L. Mathias

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

E. Vichinsky, A. Kutlar, T. Coates, 2011, British journal of haematology.

Gene therapy for Wiskott-Aldrich syndrome-long - Term efficacy and genotoxicity (Science Translational Medicine)

D. Steinemann, A. Schambach, W. Al-Herz, 2014 .

Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity

Michael Rothe, Christof von Kalle, Raffaele Fronza, 2014, Science Translational Medicine.

Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis

L. Diller, C. Moertel, J. Dome, 2008, Pediatric blood & cancer.

Efficacy of Gene Therapy for Wiskott-Aldrich-Syndrome

W. Al-Herz, C. Klein, A. Schwarzer, 2011 .